Abstract
Combination therapy has birthed improved treatment possibilities for a number of complex and degenerative diseases in the world, which include cancer, diabetes and cardiovascular disease, and has been encouraged for use in the treatment of Alzheimer’s disease (AD), as a result of its complex pathological pathways. The combination of memantine and donepezil was approved for use to treat moderate-to-severe AD cases in 2014. Studies have however continued to investigate many other possible combination therapies for the treatment of AD. This article highlights some of the recent combination therapies involving the use of donepezil.
This is a preview of subscription content, log in via an institution to check access.
Reproduced with permission from Shabab, T, International Journal of Neuroscience; published by Taylor & Francis Online, 2016
Reproduced with permission from Shabab, T, International Journal of Neuroscience; published by Taylor & Francis Online, 2016
Similar content being viewed by others
Data availability
The authors confirm that the data supporting the findings of this study are available within the article.
Change history
24 June 2023
A Correction to this paper has been published: https://doi.org/10.1007/s00580-023-03497-8
References
Arai H, Takahashi TA (2009) Combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatr 17(4):353–354. https://doi.org/10.1097/JGP.0b013e31819431ea
Aykac A, Özbeyli D, Pekol G, Sehirli AO (2021) Evaluation of the effects of donepezil, memantine and alpha-lipoic acid combined administration in amnesia rats on impaired cognitive functions in terms of behavioural, apoptotic, cholinergic and glutamatergic systems. Clin Exp Health Sci 11(4):733–741. https://doi.org/10.33808/clinexphealthsci.856459
Bhushan I, Access O, Kour M, Kour G, Gupta S, Sharma S, Yadav A (2018) Alzheimer’s disease: causes and treatment-a review. Ann Biotech 1(1):1002
Bir SC, Khan MW, Javalkar V, Toledo EG, Kelley RE (2021) Emerging concepts in vascular dementia: a review. J Stroke Cerebrovasc Dis 30(8):105864. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105864
Briggs RA, Kennelly SP, Desmond OC (2016a) Drug treatments in Alzheimer’s disease. Clin Med 16(3):247–253
Briggs R, Kennelly SP, O’Neill D (2016b) Drug treatments in Alzheimer’s disease. Clin Med (lond) 16(3):247–253. https://doi.org/10.7861/clinmedicine.16-3-247
Carpentier P, Testylier G, Baille V, Dhote F, Job A, Pouyatos B (2008) Soman-induced seizures and related brain damage: how to treat seizures and assess their effects non-invasively? J Med Chem Biol Radiol Def 6:1–16
Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K (2022) Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y) 8(1):e12295. https://doi.org/10.1002/trc2.12295
Cummings JL, Tong G, Ballard C (2019) Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis 67(3):779–794. https://doi.org/10.3233/JAD-180766
Droguerre M, Duchêne A, Picoli C, Portal B, Lejards C, Guiard BP, Meunier J, Villard V, Déglon N, Hamon M, Mouthon F, Charvériat M (2020) Efficacy of THN201, a combination of donepezil and mefloquine, to reverse neurocognitive deficits in Alzheimer’s disease. Front Neurosci 14:563. https://doi.org/10.3389/fnins.2020.00563
Duboisa B, Padovanib A, Scheltensc P, Rossid A, Agnello GD (2015) Timely diagnosis for Alzheimer’s disease: a literature review on benefits and challenges. J Alz Dis 49(3):617–631. https://doi.org/10.3233/JAD-150692
Ekundayo BE, Obafemi O, Afolabi B, Adewale OB, Onasanya A, Osukoya O, Falode JA, Akintayo C, Adu I (2022) Gallic acid and hesperidin elevate neurotransmitters level and protect against oxidative stress, inflammation and apoptosis in aluminum chloride-induced Alzheimer’s disease in rats. Pharmacol Res Modern Chinese Med 5:100193. https://doi.org/10.1016/j.prmcm.2022.100193
Fang X, Zhang J, Zhao J, Wang L (2022) Effect of resveratrol combined with donepezil hydrochloride on inflammatory factor level and cognitive function level of patients with Alzheimer’s disease. J Healthc Eng 2022:9148650. https://doi.org/10.1155/2022/9148650
Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P (2019) Combination therapy for Alzheimer’s disease: perspectives of the EU/US CTAD task force. J Prev Alzheimers Dis 6(3):164–168. https://doi.org/10.14283/jpad.2019.12
Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, Lanman L, Chadha AS, van der Flier WM (2023) Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement 19(2):658–670. https://doi.org/10.1002/alz.12694
Haug KH, Myhrer T, Fonnum F (2007) The combination of donepezil and procyclidine protects against soman-induced seizures in rats. Toxicol Appl Pharmacol 220(2):156–163. https://doi.org/10.1016/j.taap.2006.12.023
Heo HJ, Park SY, Lee YS, Shin HK, Hong KW, Kim CD (2020) Combination therapy with cilostazol, aripiprazole, and donepezil protects neuronal cells from β-amyloid neurotoxicity through synergistically enhanced SIRT1 expression. Korean J Physiol Pharmacol 24(4):299–310. https://doi.org/10.4196/kjpp.2020.24.4.299
Hajjo R, Sabbah DA, Abusara OH, Al Bawab AQ (2022) A review of the recent advances in Alzheimer’s disease research and the utilization of network biology approaches for prioritizing diagnostics and therapeutics. Diagnostics (basel) 12(12):2975. https://doi.org/10.3390/diagnostics12122975
Ihara M, Nishino M, Taguchi A, Yamamoto Y, Hattori Y, Saito S, Takahashi Y, Tsuji M, Kasahara Y, Takata Y, Okada M (2014) Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. PLoS One 9(2):e89516. https://doi.org/10.1371/journal.pone.0089516
Jelic V, Darreh-Shori T (2010). Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clin Med Insights: Ther 2:771–788. https://doi.org/10.4137/CMT.S5410
Jotheeswaran AT, Williams JD, Prince MJ (2018) The predictive validity of the 10/66 dementia diagnosis in Chennai, India: a 3-year follow-up study of cases identified at baseline. Alz Dis Assoc Disord 24(3):296–301
Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM (2020) Combination drug therapy for the management of Alzheimer’s disease. Int J Mol Sci 21(9):3272. https://doi.org/10.3390/ijms21093272
Keshk AG, ElFiky SR, AlSharaky DR, ElBatsh MM (2021) Antiamnestic effect of co-administration of losartan and donepezil in l-methionine-induced vascular dementia in rats. Menoufia Med J 35(1):48–54. https://doi.org/10.4103/mmj.mmj_49_21
Klatte ET, Scharre DW, Nagaraja HN, Davis RA, Beversdorf DQ (2003) Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 17(2):113–116. https://doi.org/10.1097/00002093-200304000-00010
Khodir SA, Faried MA, Abd-Elhafiz HI, Sweed EM (2022) Sitagliptin attenuates the cognitive deficits in L-methionine-induced vascular dementia in rats. Biomed Res Int 2022:7222590. https://doi.org/10.1155/2022/7222590
Lee JH, Park SY, Shin YW, Kim CD, Lee WS, Hong KW (2007) Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 1185:246–255. https://doi.org/10.1016/j.brainres.2007.09.016
Lee JY, Lee H, Yoo HB, Choi JS, Jung HY, Yoon EJ, Kim H, Jung YH, Lee HY, Kim YK (2019) Efficacy of cilostazol administration in Alzheimer’s disease patients with white matter lesions: a positron-emission tomography study. Neurotherapeutics 16(2):394–403. https://doi.org/10.1007/s13311-018-00708-x
Li D, Zhou Y, Yang H (2012) Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer’s disease: a 20-week open-label pilot study. Int J Med Sci 9(3):248–255. https://doi.org/10.7150/ijms.4363
Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179(2):312–339. https://doi.org/10.1016/j.cell.2019.09.001
Ma F, Chen T, Wang Y, Xu J (2022) Effect of a combination of donepezil tablets and butylphthalide soft capsules on neurological function in dementia patients, and its effect on serum inflammatory factors. Trop J Pharm Res 22(2). https://doi.org/10.4314/tjpr.v22i2.21
Manjare R, Tilak A, Bhalchandra R, Dabhade S, Bhalsinge R, Patil H (2014) Study of effects of donepezil and aspirin on working memory in rats using electroconvulsive shock model. Int J BasClin Pharmacol 1012. https://doi.org/10.5455/2319-2003.ijbcp20141210
Malve HO (2017) Management of Alzheimer’s disease: role of existing therapies, traditional medicines and new treatment targets. Indian J Pharm Sci 79(1):2–15
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease (2021). Neuropharmacology 190:108352. https://doi.org/10.1016/j.neuropharm.2020.108352
McDonough JH, McMonagle JD, Capacio BR (2022) Anticonvulsant effectiveness of scopolamine against soman-induced seizures in African green monkeys. Drug Chem Toxicol 45(5):2185–2192. https://doi.org/10.1080/01480545.2021.1916171
Pardo-Moreno T, González-Acedo A, Rivas-Domínguez A, García-Morales V, García-Cozar FJ, Ramos-Rodríguez JJ, Melguizo-Rodríguez L (2022) Therapeutic approach to Alzheimer’s disease: current treatments and new perspectives. Pharmaceutics 14(6):1117. https://doi.org/10.3390/pharmaceutics14061117
Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I (2021) Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis 8(3):371–386. https://doi.org/10.14283/jpad.2021.23 PMID: 34101796
Pradeep S, Jain AS, Dharmashekara C, Prasad SK, Kollur SP, Syed A, Shivamallu C (2020) Alzheimer’s disease and herbal combination therapy: a comprehensive review. J Alzheimers Dis Rep 4(1):417–429. https://doi.org/10.3233/ADR-200228
Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, Mohan G (2017) Neuroinflammation pathways: a general review. Int J Neurosci 127:624–633
Stein C, Hopfeld J, Lau H, Klein J (2015) Effects of Ginkgo biloba extract EGb 761, donepezil and their combination on central cholinergic function in aged rats. J Pharm Pharm Sci 18(4):634–646. https://doi.org/10.18433/j3wc8v
Sugimoto H, Ogura H, Arai Y, Limura Y, Yamanishi Y (2002) Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 89(1):7–20. https://doi.org/10.1254/jjp.89.7
Sultan S, Al-Hamady M, Hafiz AH, Al-Barakati AM, Al-Huthali RK, Al-Jahdali NH (2018) An update on treatment of Alzheimer’s disease- a literature review. Eur J Pharm Med Res 5(7):9–18
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M (2019) Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomed 14:5541–5554. https://doi.org/10.2147/IJN.S200490
Wolters FJ, Ikram MA (2019) Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol 39(8):1542–1549. https://doi.org/10.1161/ATVBAHA.119.311908
Zhang X, Yu R, Wang H, Zheng R (2020) Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer’s disease. Exp Ther Med 20(2):1789–1795. https://doi.org/10.3892/etm.2020.8872
Zhang Y, Wang Y, Zhang C, Li H, Li J, Luo Y, Liu D, Bai H (2016) Pharmacological study of nimodipine plus donepezil in treating senile dementia. Int J Clin Exp Med 9(2):4497–4502
Author information
Authors and Affiliations
Contributions
All authors contributed equally to the writing, proof reading, correction and preparation of the draft and final copy of the manuscript.
Corresponding author
Ethics declarations
Funding
This study was not supported by any funding.
Conflict of interest
The authors declare no competing interest.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
For this type of study informed consent is not required.
Consent for publication
The authors give their consent for publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised: This article was originally published with a misspelled author name. The correct author name presentation should be Babatunji Emmanuel Oyinloye.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ekundayo, B.E., Obafemi, T.O., Adewale, O.B. et al. Donepezil-based combination therapy for Alzheimer’s disease and related neuropathies. Comp Clin Pathol 32, 699–708 (2023). https://doi.org/10.1007/s00580-023-03487-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-023-03487-w